Biocon Gains India Approval for Liraglutide

  Published 1 year ago

Biocon Pharma received CDSCO approval for its generic Liraglutide, a drug for type 2 diabetes, using the streamlined '101 route'. This initiative aims to increase access to affordable diabetes treatment in India, where the disease has a high prevalence.

  • Generic version of Victoza approved in India.
  • Approval via CDSCO’s ‘101 route’ for faster access.
  • Addresses the growing diabetes epidemic in India.

You might like these

Rupee Nears Record Low on Trump Tariff Threat

India Uses Record Rice for Ethanol Amid Surplus

Aurionpro Bags African Bank Deal

Airtel Q1 PBT Doubles, Revenue Up 28.5%

Tata Consumer Rises on Margin Hopes

Hero MotoCorp E-Scooter Battery Rental Faces Criticism

Oil Stocks Rise on Geopolitical Tensions, High Crude Prices

News that matters the most ⚡